TABLE 2.

Nasal immunization of CPMV-MAST1 without adjuvant better primes carrier CPMV-specific T cells than oral immunization^a

Group (route)	Mean cpm ± SD (SI) with:
	CPMV		ConA (2.5 μg/ml)
	50 μg/ml	5 μg/ml
CPMV-MAST1 (intranasal)	8,288 ± 730b (22.4)	5,291 ± 719b (14.3)	19,462 ± 3,177 (52.6)
CPMV-MAST1 (oral)	3,156 ± 287c (10.3)	2,203 ± 321c (6.8)	17,859 ± 2,965 (48.5)
Unimmunized	2,079 ± 296 (7.4)	1,208 ± 291 (4.3)	14,500 ± 3,405 (51.3)

^aMice were immunized intranasally or orally with 100 μg of CPMV-MAST1 without adjuvant on days 0, 7, 14, and 21. On day 42 (oral) and day 49 (nasal) spleen cells were removed and cultured either alone (medium), with 2.5 μg of ConA per ml, or with 50 or 5 μg of CPMV per ml for 5 days. Spleen cells from unimmunized mice were tested as a control for nonspecific proliferation. Incorporation of [³H]thymidine was measured in the last 6 h of culture. 

^bP < 0.001. 

^cP < 0.05.